Stephens Reiterates “Overweight” Rating for Nurix Therapeutics (NASDAQ:NRIX)
Nurix Therapeutics (NASDAQ:NRIX – Get Free Report)‘s stock had its “overweight” rating restated by Stephens in a report issued on Tuesday,Benzinga reports. They currently have a $31.00 target price on ...
Nurix Therapeutics, Inc.: Nurix Therapeutics Announces Appointment of John Northcott as Chief Commercial Officer
Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients ...
Nurix Therapeutics appoints new chief commercial officer
SAN FRANCISCO - Nurix Therapeutics, Inc. (NASDAQ:NRIX), a biopharmaceutical company specializing in targeted protein modulation drugs, announced today the appointment of John Northcott as its new ...
Nurix Therapeutics appoints John Northcott as CCO
Nurix Therapeutics (NRIX) announced the appointment of John Northcott as chief commercial officer. From 2022 through 2024, Mr. Northcott served ...
Taiwan News5d
ORYZON announces appointment of Dr. Pierre Beaurang as Strategy and Business Development Advisor
Dr. Beaurang has over 25 years of experience in biotechnology focusing on corporate strategy, business development, oncology, immunology and neurology. Dr. Beaurang was most recently CEO and member of ...
Nurix Therapeutics: Strategic Pipeline Developments and Market Expansion Justify Buy Rating
In a report released today, Jeet Mukherjee from BTIG maintained a Buy rating on Nurix Therapeutics (NRIX – Research Report), with a price ...